Postfracture care among women, men and all patients combined for each of the interventions studied
| Care received | Usual care, no. (%, 95% CI) | Physician notification, no. (%, 95% CI) | Physician and patient notification, no. (%, 95% CI) | Combined notification, no. (%, 95% CI) |
|---|---|---|---|---|
| Women only | n = 990 | n = 920 | n = 931 | n = 1851 |
| Bone mineral density testing | 56 (5.7, 4.2–7.1) | 171 (18.6, 15.9–21.3) | 204 (21.9, 19.4–24.4) | 375 (20.3, 18.4–22.1) |
| Pharmacologic treatment | 121 (12.2, 10.2–14.3) | 156 (17.0, 14.4–19.5) | 181 (19.4, 17.0–21.9) | 337 (18.2, 16.4–20.0) |
| Testing or treatment | 156 (15.8, 13.5–18.0) | 279 (30.3, 27.3–33.4) | 317 (34.0, 31.1–37.0) | 596 (32.2, 30.1–34.3) |
| Men only | n = 490 | n = 443 | n = 490 | n = 933 |
| Bone mineral density testing | 2 (0.4, 0.0–1.0) | 53 (11.9, 9.0–14.9) | 54 (11.0, 8.1–13.9) | 107 (11.5, 9.4–13.5) |
| Pharmacologic treatment | 36 (7.3, 5.0–9.7) | 44 (9.9, 7.0–12.8) | 53 (10.8, 8.2–13.5) | 97 (10.4, 8.4–12.4) |
| Testing or treatment | 37 (7.6, 2.0–9.9) | 84 (19.0, 15.3–22.7) | 97 (19.8, 16.3–23.3) | 181 (19.4, 16.9–21.9) |
| All patients combined | n = 1480 | n = 1363 | n = 1421 | n = 2784 |
| Bone mineral density testing | 58 (3.9, 2.9–4.9) | 224 (16.4, 14.4–18.5) | 258 (18.2, 16.2–20.1) | 482 (17.3, 15.9–18.7) |
| Pharmacologic treatment | 157 (10.6, 9.0–12.2) | 200 (14.7, 12.7–16.6) | 234 (16.5, 14.6–18.3) | 434 (15.6, 14.2–16.9) |
| Testing or treatment | 193 (13.0, 11.3–14.8) | 363 (26.6, 24.2–29.0) | 414 (29.1, 26.8–31.4) | 777 (27.9, 26.2–29.6) |
Note: CI = confidence interval.